Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

Carlo Gambacorti-Passerini, Hagop M. Kantarjian, Dong Wook Kim, Hanna J. Khoury, Anna G. Turkina, Tim H. Brümmendorf, Ewa Matczak, Nathalie Bardy-Bouxin, Mark Shapiro, Kathleen Turnbull, Eric Leip, Jorge E. Cortes

Research output: Contribution to journalArticle

Abstract

Long-term efficacy and safety of bosutinib (≥4 years follow-up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure (accelerated-phase [AP, n = 79] chronic myeloid leukemia [CML], blast-phase [BP, n = 64] CML, acute lymphoblastic leukemia [ALL, n = 24]). Fourteen AP, 2 BP, and 1 ALL patient remained on bosutinib at 4 years (vs. 38, 8, 1 at 1 year); median (range) treatment durations: 10.2 (0.1-88.6), 2.8 (0.03-55.9), 0.97 (0.3-89.2) months. Among AP and BP patients, 57% and 28% newly attained or maintained baseline overall hematologic response (OHR); 40% and 37% attained/maintained major cytogenetic response (MCyR) by 4 years (most by 12 months). In responders at 1 versus 4 years, Kaplan-Meier (KM) probabilities of maintaining OHR were 78% versus 49% (AP) and 28% versus 19% (BP); KM probabilities of maintaining MCyR were 65% versus 49% (AP) and 21% versus 21% (BP). Most common AEs (AP, BP) were gastrointestinal (96%; 83%), primarily diarrhea (85%; 64%), which was typically low grade (maximum grade 1/2: 81%; 59%) and transient; no patient discontinued due to diarrhea. Serious AEs occurred in 44 (56%) AP and 37 (58%) BP patients, most commonly pneumonia (n = 9) for AP and pyrexia (n = 6) for BP; 11 and 13 died within 30 days of last dose (2 considered bosutinib-related [AP] per investigator). Responses were durable in ∼50% AP responders at 4 years (∼25% BP patients responded at year 1, suggesting possible bridge-to-transplant role in BP patients); toxicity was manageable.

Original languageEnglish (US)
Pages (from-to)755-768
Number of pages14
JournalAmerican Journal of Hematology
Volume90
Issue number9
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Protein-Tyrosine Kinases
Leukemia
Safety
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Diarrhea
Blast Crisis
Imatinib Mesylate
bosutinib
Treatment Failure
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pneumonia
Fever
Research Personnel
Transplants

ASJC Scopus subject areas

  • Hematology

Cite this

Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. / Gambacorti-Passerini, Carlo; Kantarjian, Hagop M.; Kim, Dong Wook; Khoury, Hanna J.; Turkina, Anna G.; Brümmendorf, Tim H.; Matczak, Ewa; Bardy-Bouxin, Nathalie; Shapiro, Mark; Turnbull, Kathleen; Leip, Eric; Cortes, Jorge E.

In: American Journal of Hematology, Vol. 90, No. 9, 01.09.2015, p. 755-768.

Research output: Contribution to journalArticle

Gambacorti-Passerini, C, Kantarjian, HM, Kim, DW, Khoury, HJ, Turkina, AG, Brümmendorf, TH, Matczak, E, Bardy-Bouxin, N, Shapiro, M, Turnbull, K, Leip, E & Cortes, JE 2015, 'Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors', American Journal of Hematology, vol. 90, no. 9, pp. 755-768. https://doi.org/10.1002/ajh.24034
Gambacorti-Passerini, Carlo ; Kantarjian, Hagop M. ; Kim, Dong Wook ; Khoury, Hanna J. ; Turkina, Anna G. ; Brümmendorf, Tim H. ; Matczak, Ewa ; Bardy-Bouxin, Nathalie ; Shapiro, Mark ; Turnbull, Kathleen ; Leip, Eric ; Cortes, Jorge E. / Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. In: American Journal of Hematology. 2015 ; Vol. 90, No. 9. pp. 755-768.
@article{056e35f6d12342519e834775f9615310,
title = "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors",
abstract = "Long-term efficacy and safety of bosutinib (≥4 years follow-up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure (accelerated-phase [AP, n = 79] chronic myeloid leukemia [CML], blast-phase [BP, n = 64] CML, acute lymphoblastic leukemia [ALL, n = 24]). Fourteen AP, 2 BP, and 1 ALL patient remained on bosutinib at 4 years (vs. 38, 8, 1 at 1 year); median (range) treatment durations: 10.2 (0.1-88.6), 2.8 (0.03-55.9), 0.97 (0.3-89.2) months. Among AP and BP patients, 57{\%} and 28{\%} newly attained or maintained baseline overall hematologic response (OHR); 40{\%} and 37{\%} attained/maintained major cytogenetic response (MCyR) by 4 years (most by 12 months). In responders at 1 versus 4 years, Kaplan-Meier (KM) probabilities of maintaining OHR were 78{\%} versus 49{\%} (AP) and 28{\%} versus 19{\%} (BP); KM probabilities of maintaining MCyR were 65{\%} versus 49{\%} (AP) and 21{\%} versus 21{\%} (BP). Most common AEs (AP, BP) were gastrointestinal (96{\%}; 83{\%}), primarily diarrhea (85{\%}; 64{\%}), which was typically low grade (maximum grade 1/2: 81{\%}; 59{\%}) and transient; no patient discontinued due to diarrhea. Serious AEs occurred in 44 (56{\%}) AP and 37 (58{\%}) BP patients, most commonly pneumonia (n = 9) for AP and pyrexia (n = 6) for BP; 11 and 13 died within 30 days of last dose (2 considered bosutinib-related [AP] per investigator). Responses were durable in ∼50{\%} AP responders at 4 years (∼25{\%} BP patients responded at year 1, suggesting possible bridge-to-transplant role in BP patients); toxicity was manageable.",
author = "Carlo Gambacorti-Passerini and Kantarjian, {Hagop M.} and Kim, {Dong Wook} and Khoury, {Hanna J.} and Turkina, {Anna G.} and Br{\"u}mmendorf, {Tim H.} and Ewa Matczak and Nathalie Bardy-Bouxin and Mark Shapiro and Kathleen Turnbull and Eric Leip and Cortes, {Jorge E.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/ajh.24034",
language = "English (US)",
volume = "90",
pages = "755--768",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

AU - Gambacorti-Passerini, Carlo

AU - Kantarjian, Hagop M.

AU - Kim, Dong Wook

AU - Khoury, Hanna J.

AU - Turkina, Anna G.

AU - Brümmendorf, Tim H.

AU - Matczak, Ewa

AU - Bardy-Bouxin, Nathalie

AU - Shapiro, Mark

AU - Turnbull, Kathleen

AU - Leip, Eric

AU - Cortes, Jorge E.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Long-term efficacy and safety of bosutinib (≥4 years follow-up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure (accelerated-phase [AP, n = 79] chronic myeloid leukemia [CML], blast-phase [BP, n = 64] CML, acute lymphoblastic leukemia [ALL, n = 24]). Fourteen AP, 2 BP, and 1 ALL patient remained on bosutinib at 4 years (vs. 38, 8, 1 at 1 year); median (range) treatment durations: 10.2 (0.1-88.6), 2.8 (0.03-55.9), 0.97 (0.3-89.2) months. Among AP and BP patients, 57% and 28% newly attained or maintained baseline overall hematologic response (OHR); 40% and 37% attained/maintained major cytogenetic response (MCyR) by 4 years (most by 12 months). In responders at 1 versus 4 years, Kaplan-Meier (KM) probabilities of maintaining OHR were 78% versus 49% (AP) and 28% versus 19% (BP); KM probabilities of maintaining MCyR were 65% versus 49% (AP) and 21% versus 21% (BP). Most common AEs (AP, BP) were gastrointestinal (96%; 83%), primarily diarrhea (85%; 64%), which was typically low grade (maximum grade 1/2: 81%; 59%) and transient; no patient discontinued due to diarrhea. Serious AEs occurred in 44 (56%) AP and 37 (58%) BP patients, most commonly pneumonia (n = 9) for AP and pyrexia (n = 6) for BP; 11 and 13 died within 30 days of last dose (2 considered bosutinib-related [AP] per investigator). Responses were durable in ∼50% AP responders at 4 years (∼25% BP patients responded at year 1, suggesting possible bridge-to-transplant role in BP patients); toxicity was manageable.

AB - Long-term efficacy and safety of bosutinib (≥4 years follow-up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure (accelerated-phase [AP, n = 79] chronic myeloid leukemia [CML], blast-phase [BP, n = 64] CML, acute lymphoblastic leukemia [ALL, n = 24]). Fourteen AP, 2 BP, and 1 ALL patient remained on bosutinib at 4 years (vs. 38, 8, 1 at 1 year); median (range) treatment durations: 10.2 (0.1-88.6), 2.8 (0.03-55.9), 0.97 (0.3-89.2) months. Among AP and BP patients, 57% and 28% newly attained or maintained baseline overall hematologic response (OHR); 40% and 37% attained/maintained major cytogenetic response (MCyR) by 4 years (most by 12 months). In responders at 1 versus 4 years, Kaplan-Meier (KM) probabilities of maintaining OHR were 78% versus 49% (AP) and 28% versus 19% (BP); KM probabilities of maintaining MCyR were 65% versus 49% (AP) and 21% versus 21% (BP). Most common AEs (AP, BP) were gastrointestinal (96%; 83%), primarily diarrhea (85%; 64%), which was typically low grade (maximum grade 1/2: 81%; 59%) and transient; no patient discontinued due to diarrhea. Serious AEs occurred in 44 (56%) AP and 37 (58%) BP patients, most commonly pneumonia (n = 9) for AP and pyrexia (n = 6) for BP; 11 and 13 died within 30 days of last dose (2 considered bosutinib-related [AP] per investigator). Responses were durable in ∼50% AP responders at 4 years (∼25% BP patients responded at year 1, suggesting possible bridge-to-transplant role in BP patients); toxicity was manageable.

UR - http://www.scopus.com/inward/record.url?scp=84939565243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939565243&partnerID=8YFLogxK

U2 - 10.1002/ajh.24034

DO - 10.1002/ajh.24034

M3 - Article

C2 - 26040495

AN - SCOPUS:84939565243

VL - 90

SP - 755

EP - 768

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 9

ER -